Consequences of Pressure Overload on Sarcomere Protein Mutation-induced Hypertrophic Cardiomyopathy
Overview
Authors
Affiliations
Background: Whether ventricular remodeling from hypertrophic cardiomyopathy (HCM), systemic hypertension, or other pathologies arises through a common signaling pathway or through independent molecular mechanisms is unknown. To study this, we assessed cardiac hypertrophy in a mouse model of HCM subjected to increased left ventricular (LV) load.
Methods And Results: Transverse aortic banding of mice with or without an Arg403Gln cardiac myosin heavy chain mutation (alphaMHC403/+) produced similarly elevated LV pressures (120+/-30 versus 112+/-14 mm Hg; P=NS). No mice developed heart failure, and mortality (26% alphaMHC403/+, 35% wild-type) was comparable. Load-induced hypertrophy was identical in banded 129SvEv alphaMHC403/+ mice (LV anterior wall [LVAW]=1.28+/-0.11) and 129SvEv wild-type mice (LVAW=1.29+/-0.11 mm; P=NS). Genetically outbred Black Swiss (BS) alphaMHC403/+ mice showed only mildly exaggerated hypertrophy in response to aortic banding (BS alphaMHC403/+ LVAW=1.30+/-0.13 mm; BS wild-type LVAW=1.17+/-0.15 mm; P=0.03), suggesting some effect from a BS genetic locus that modifies hypertrophy induced by the cardiac MHC Arg403Gln mutation. Histopathology and molecular markers of hypertrophy were comparable in all banded 129SvEv or BS mice. Banded alphaMHC403/+ mice had potential for greater hypertrophy, because cyclosporin A treatment markedly augmented hypertrophy.
Conclusions: The uniform hypertrophic response to increased ventricular load in wild-type and alphaMHC403/+ mice indicates independent cardiac remodeling pathways and predicts that coexistent hypertension and HCM should not profoundly exacerbate cardiac hypertrophy. In contrast, sarcomere mutation and cyclosporin A-mediated calcineurin inhibition stimulate a shared hypertrophic signaling pathway. Defining distinct signaling pathways that trigger myocyte growth should help to tailor therapies for cardiac hypertrophy.
Dynamic control of contractile resistance to iPSC-derived micro-heart muscle arrays.
Schuftan D, Kargar Gaz Kooh Y, Guo J, Sun Y, Aryan L, Stottlemire B J Biomed Mater Res A. 2023; 112(4):534-548.
PMID: 37952251 PMC: 10922390. DOI: 10.1002/jbm.a.37642.
Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation.
Funk F, Kronenbitter A, Hackert K, Oebbeke M, Klebe G, Barth M Cardiovasc Res. 2023; 119(7):1568-1582.
PMID: 36869774 PMC: 10318394. DOI: 10.1093/cvr/cvad037.
Guo J, Jiang H, Oguntuyo K, Rios B, Boodram Z, Huebsch N Cell Mol Bioeng. 2021; 14(5):409-425.
PMID: 34777601 PMC: 8548480. DOI: 10.1007/s12195-021-00684-x.
Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
Lorenzini M, Norrish G, Field E, Ochoa J, Cicerchia M, Akhtar M J Am Coll Cardiol. 2020; 76(5):550-559.
PMID: 32731933 PMC: 7397507. DOI: 10.1016/j.jacc.2020.06.011.
Eberly L, Day S, Ashley E, Jacoby D, Jefferies J, Colan S JAMA Cardiol. 2019; 5(1):83-91.
PMID: 31799990 PMC: 6902181. DOI: 10.1001/jamacardio.2019.4638.